NCT04073537 - Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

386

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

June 30, 2022

Conditions

Squamous Non-small Cell Lung Cancer

Interventions

DRUG

Anlotinib

A multi-target receptor tyrosine kinase inhibitor.

DRUG

Placebos

Anlotinib blank analog capsule.

DRUG

Paclitaxel

Paclitaxel 175 mg/m\^2 IV on Day 1 of each 21-day cycle.

DRUG

Carboplatin

Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.

Trial Locations (2)

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Cancer Hospital Chinese Academy of Medical Sciences, Beijing